Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 31792610 | HLA (HLA) | wounds | NA | NA | NA | positive | |
| cd11c+hla-dra+ dcs were first observed in skin wounds with postinfliction intervals of 3 days, and the dc numbers were found to be elevated in skin wounds with the subsequent increase in postinfliction intervals. | |||||||
| 12694665 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | cervical cancers | NA | NA | NA | lack_of_evidence | |
| this may be clinically relevant since nk are active against cells exhibiting class i human leukocyte antigen (hla) down-regulation and many cervical cancers show loss of hla. | |||||||
| 7871759 | HLA-CLASS I (HLA CLASS II) | japanese encephalitis | Japanese | NA | NA | unclassified | |
| dengue fever virus and japanese encephalitis virus synthetic peptides, with motifs to fit hla class i haplotypes prevalent in human populations in endemic regions, can be used for application to skin langerhans cells to prime antiviral cd8+ cytotoxic t cells (ctls)--a novel approach to the protection of humans. | |||||||
| 7871759 | HLA-CLASS I (HLA CLASS II) | dengue fever | Japanese | NA | NA | unclassified | |
| dengue fever virus and japanese encephalitis virus synthetic peptides, with motifs to fit hla class i haplotypes prevalent in human populations in endemic regions, can be used for application to skin langerhans cells to prime antiviral cd8+ cytotoxic t cells (ctls)--a novel approach to the protection of humans. | |||||||
| 7871759 | HLA-CLASS I (HLA CLASS II) | dengue fever | Japanese | NA | NA | unclassified | |
| to be able to develop anti-dengue virus synthetic peptides for populations with different hla class i haplotypes, it is necessary to develop computational studies to design hla class i dengue virus synthetic peptides with motifs to fit the hla haplotypes of the population living in an endemic region for dengue fever. | |||||||
| 15105530 | HLA (HLA) | japanese encephalitis | Japanese | NA | NA | unclassified | |
| our earlier identification of the non-structural protein 3 (ns3) of japanese encephalitis virus (jev) as a dominant cd4+ as well as cd8+ t cell-eliciting antigen in a healthy jev-endemic cohort with a wide hla distribution implied the presence of several epitopes dispersed over the length of the protein. | |||||||
| 25086398 | HLA-E (HLA-E) | japanese encephalitis | Japanese | NA | NA | unclassified | |
| inhibition of erk and proliferation in nk cell lines by soluble hla-e released from japanese encephalitis virus infected cells. | |||||||
| 30581316 | MHC (MHC) | japanese encephalitis | Japanese | NA | NA | unclassified | |
| mhc binding peptides for designing of vaccines against japanese encephalitis virus: a computational approach. | |||||||
| 30906300 | HLA-DPB1 (HLA-DPB1) | japanese encephalitis | Japanese | NA | NA | unclassified | |
| hla class ii genes hla-drb1, hla-dpb1, and hla-dqb1 are associated with the antibody response to inactivated japanese encephalitis vaccine. | |||||||
| 30906300 | HLA-DRB1 (HLA-DRB1) | japanese encephalitis | Japanese | NA | NA | unclassified | |
| hla class ii genes hla-drb1, hla-dpb1, and hla-dqb1 are associated with the antibody response to inactivated japanese encephalitis vaccine. | |||||||
Copyright 2024